Male athletes may administer human chononic gonadotropin (hCG) to enhance performance. Despite imposing a ban on hCG doping, the International Olympic Committee has no recommended procedureto confirmthe presence of hCG. Our aim was to establish a limit for hCG in urine above which a sample may be considered positive. We measured hCG concentrationsin unne samples from 1400 men with the Serono MAlAclone IRMA. Statistical evaluation of the resutts gave a "far outside" value [75th percentile + (3 x interquartile range)] of 5.0 lU/L; greater values are extremely unusual. Immunoreactive material in urine samples from a reference group of 120 noncompetingindMduals was concentratedabout sevenfold by centrifugalultraflttration;allthese concentrated samples gave assay values <5.0 lU/L To ensure with the greatest possible degree of certainty that no false-positive result is reported, we propose a decision limit of 10 lU/L in nonconcentrated ultrafiltered samples. We also prepared quality-control material to contain hCG at 10 lU/L This material provides a decision limitabove which, after confirmatory procedures, a sample should be considered positive. This should help establish comparability of results among laboratories testing for sports drugs.
Male athletes may administer human chononic gonadotropin (hCG) to enhance performance. Despite imposing a ban on hCG doping, the International Olympic Committee has no recommended procedureto confirmthe presence of hCG. Our aim was to establish a limit for hCG in urine above which a sample may be considered positive. We measured hCG concentrationsin unne samples from 1400 men with the Serono MAlAclone IRMA. Statistical evaluation of the resutts gave a "far outside" value [75th percentile + (3 x interquartile range)] of 5.0 lU/L; greater values are extremely unusual. Immunoreactive material in urine samples from a reference group of 120 noncompetingindMduals was concentratedabout sevenfold by centrifugalultraflttration;allthese concentrated samples gave assay values <5.0 lU/L To ensure with the greatest possible degree of certainty that no false-positive result is reported, we propose a decision limit of 10 lU/L in nonconcentrated ultrafiltered samples. We also prepared quality-control material to contain hCG at 10 lU/L This material provides a decision limitabove which, after confirmatory procedures, a sample should be considered positive. This should help establish comparability of results among laboratories testing for sports drugs.
Indexing Terms: steroid hormones/sports medicine/screening/im-
munoradiometric assay
Human chorionicgonadotropin (hCG) may be misused by male athleteseither to stimulate endogenous testosterone production (1) (2) (3) (4) or to prevent testicular shutdown during prolonged administration of exogenous anabolic-androgenic steroids (2, 3)4 Furthermore, coadministration of hCG with testosterone may suppress changes in the testosterone/epitestosterone ratio, which is used to detect testosterone administration (5). The abifity of hCG to stimulate gonadal steroidogenesis depends on a cellular response identical to that of luteinizing hormone (LH) (6) . However, the problems of using these assays to measure the peptide and protein hormones made up of heterogeneous mixtures of molecular isoforms in these fluids are well documented (8, 9), and discordant results have been reported for hCG measured by various immunoassay kits (10, 11). Ekins and Chu (12) have suggested that, theoretically, these problems could be overcome by developing multianalyte assay systems specific and sensitive enough to allow determination of the principal components of heterogeneous mixtures. Until such systems are developed, we must use alternative approaches that will reduce discrepancies between measurements by various test centers in the context of specific applications (13) (14) (15) .
Here we show a statistical evaluation indicating that >5.0 lU/L hCG in the urine of a male athlete is abnormal. Consequently, for detecting hCG misuse in sports, we recommend a new decision limit of 10 lUlL for positive findings of hCG in ultrafiltered urine, as measured by the Serono MAlAclone immunometric assay. We also describe the preparation of a freeze-dried urinary quality-control (QC) material for hCG. Because the value for this QC is equal to the decision limit for positive findings of hCG misuse, its assay should help in the control of drug abuse in sports. In addition, when used in conjunction with assays of comparable specificity, the QC facilitates comparability of measurements of hCG concentrations among test centers. The QC is available, upon request, to interested laboratories.
Materials and Methods Samples
Single untimed urine specimens (n = 1400) collected from competing male athletes by approved sampling officers were sent to our laboratory for routine screening as part of the effort to control drug abuse in sports. by descending flow at 1 mL/ mm at room temperature in ammonium bicarbonate buffer (50 mmoIIL, adjusted to pH 8.5 with aqueous NH4OH). The eluate was monitored by absorbance at 214 nm, and 5-mL fractions were collected.
Fractions eluting in the 50-90 kDa range were analyzed for peak purity on a biocompatible HPLC incorporating a 10/30 Superose 12 column (Pharmacia LKB Biotechnology) in PBS (see Fig. 1) . A fraction that gave a symmetrical peak by HPLC was considered to have the least amounts of contaminating hCG dimer or hCG13. The fraction selected (68-74 kDa) was diluted 10-fold in ammonium bicarbonate buffer and passed through the hCG/3 aflInity column to extract hCG(3 immunoreactivity.
An aliquot of the column eluate (45P2) was added to sterilefiltered urine for preparation of the QC material for hOG.
Lyophilization.
Seven liters of urine were collected from a single healthy male volunteer over a 54-h period; the urine was stored at 4#{176}C, and thimerosal (Sigma, Poole, UK), an antimicrobial agent, was added throughout collection to give a final concentration of 0.1 g/L. BSA was added to a final concentration of 6.25 g/L and the pH was adjusted to 5.6 with 50/50 (by vol) aqueous aceticacid.After agitating the prepared urine, we ifitered it through a 1000-kDa molecular-mass-cutoff membrane, using a Minisette ultrafiltration system (Filtron Technologies UK, Wellesbourne, UK). An aliquot of the previously purified hCG preparation (45P2) was added to 5 L of the filtered urine, thoroughly mixed, and then assayed for hCG. The hOG concentration of the bulk urine solution was adjusted to 10 lU/L by addition of more filtered urine. Aliquots (1.5 mL) were then dispensed into screw-top vials and lyophilized to dryness. These QO samples were analyzed for hCG content upon reconstitution with 1.5 mL of deionized water.
Results
Assay specificity. Cross-reactions with LH and hCG/3 in the Serono hCG MAlAclone assay were determined (Fig. 2) . Relative molecular masses of 36 700, 22 200, and 29500 for hCG, hCG/3, and LH, respectively, were used to calculate the molar concentrations of the antigens. Interassay
CVs determined for 34 assays performed over 5 months were 17.2%, 11.9%, and 6.2%, respectively, for three in-house urinary hCG quality controls (prepared from hCG elimination urines) having mean assay values of 5.1, 9.3, and 27.7 IU!L. The analytical performance of the comparison assay (ELSA-Fb HCG) has been described earlier (20) . 
greater than this is extremely unusual (18).
Assay values from direct measurements of the urine specimens may result either from hCG or from nonspecific interference; however, without the removal of potential contaminants by centrifugal ultrafiltration, it is impossible to assess the contribution of each component. Nevertheless, regardless of the contribution from nonspecific effects, limits of abnormality can be set for screening purposes.
Reference values for 120 healthy individuals. Comparison of 3rd IS for hCG (75/53 7) and QC material for hCG. The hOG reference material (45P2) prepared for our QC samples and the 3rd IS for hCG (75/ 537) were analyzed for intact hOG and hCGI3 content. Our reference preparation of hOG has 3.4 times less hCG/3 immunoreactivity than the 3rd IS (see Table 1 ).
DIscussion
The threshold of 25 lU/L for hOG in urine, previously used in our laboratory to detect hCG abuse in sports, had been set after the screening of 740 urine samples in 1987 (7). Data collected since then have indicated that a lower threshold might be valid.Analysis of the data from 1400 urine samples showed that the distribution of hCG concentrations was positively skewed, primarily because of three outlying values (one >5 lU/b, two >20 lU/L). Considering that the urines originated from athletes, the abnormal values might be due to individual abuse of hOG; however, we also considered the possibility of undiagnosed hCG-secreting malignancies. In the US, the incidence of hOG-secreting testicular tumors in men of ages 20-35 years is 2-3 per 100 000 (21). Thus, even if there were a relatively large difference between the US population and ours, this incidence is considerably less than the frequency of abnormal values of hCG observed in our study, indicating hOG administration.
Although our limit for abnormality was set at 5.0
IU/L, we propose using 10 lU/L as our decision limit for a positive finding.This cutoff is twice the value of the "far outside" value but much lower than the previous threshold.
In our laboratory, any urine yielding hOG >5.0 lU/b by routine screening is subjected to a further assay after ultrafiltration (without sevenfold concentration). If the second assay result is stifi >5.0 lU/L but <10 lU/L, the urine would be deemed negative; nevertheless, reportsof their abnormality would be made to the appropriate authorities. An assay value >10 lU/L constitutes a positive finding and would be reported accordingly.
An athlete with an unusually high concentration of hCG in his urine who denies having taken hOG is strongly advised to seek medical advice because hCG is secreted by both trophoblastic and nontrophoblastic tumors (14, 22) . This finding could thus be a singularpiece of good fortune for the athlete.
Urine samples obtained from 120 healthy reference group individuals selected randomly, direct from the population at large (16, 17), were analyzed for hOG 
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Assay calibrated against 3rd IS for hCG (75/537) Inserum. 108 ng was taken as beingequivalent to I IU of hCG and 1 zg wastaken as beingequivalent to 1 IU of hCG.
C Relativemolecularmasses0136 700 for hCG and 22200 for hCG were used to calculate molarconcentrations. For drug control in sports, we wish to distinguish, with the greatest degree of certainty possible, a male athlete with an abnormally large concentration of hOG in urine from the healthy adult male population. To give the degree of certainty required for confirmation of a positive finding, we keep a large margin between the limit of abnormality and the decision limit for a positive finding. Effortsto eradicate these phenomena and to improve standardization between laboratories must be made (14) . To aid reliability, reproducibility, and comparability of interlaboratory results, we have produced a freezedried QO material for hOG in a urinary matrix at the decision limit for positive findings as determined by our methods.
This material, initially separated by sizeexclusion chromatography, was passed through a hOGf3 immunoaflinity column to increase its immunoreactive purity. The antibody bound to the affinity column is directed against the epitope designated f37 on hOG, an epitope that is masked on intact hOG but revealed on hCG/3 and the core fragment of hCGI3 (hCG/3cf) (19). This allowed us to remove hCGI3 and hOGf3cf immunoreactivity from our material; indeed, for hCG immunoreactivity our preparation was 3.4 times more pure than the 3rd IS for hOG. We believe that the material we produced for incorporation into the QO samples for hCG contains fewer of the isoforms that generally constitute hOG immunoreactivity, especially the free subunits of hOG and hCGJ3cf.
Although we hope that decision limits set in our laboratories for determining positive findings of hOG in urine can be adopted by the other 100-accredited laboratories and used with our characterized QO material to demonstrate positive findings, the values obtained by different procedures may not be directly comparable because of variations in calibration, detection limits, and specificity (14). However, given the fewer variants of hOG in the QC material, the results for the material should be comparable even when measured in different assays. According to data from the UK EQAS (14,24), Serono hCG M.AIAclone, despite its poor response to hOG(3, hOG(3cf, and "nicked" hOG (hOGn) (11), gave results comparable with those from the Pharmacia Delfia., Hybritech Tandem-R, and Abbott IMx (Intact) assays for samples containing intact hOG distributed within the scheme. The value given by the QC sample should be considered the decision limit for positive findings, and any sample giving a greater value on initial screening should be a candidate for subsequent confirmation. Although individual samples may give discordant results in different assays because of variable recognition of the molecular isoforms present, the use of assays measuring intact or biologically active hOG should minimize this possibility.
The Serono MAlAclone, an hOG + hCGp assay of f3-af3If3 type, is designed primarily to measure whole hOG. However, in cases of extremely high concentrations of hCG and hCG/3, a high-dose "hook effect" is avoided by the inclusion of a second labeled antibody against hCGIS. This antibody has a low affinity for hOGJ3 (see Fig. 2 ), so contributions to assay values at the hOG concentrations presented in the detection of hCG misuse in sports may be considered negligible.
To give a value of 10 lU/L in the Serono MAlAclone assay, 450 pmol/b hOG/3 (1st IRP, 75/551) is required, 15-fold more hCGJ3 than the amount of hOG necessary to give the same value. This is an enormous quantity and is likely to arise only from malignant disease (22). hOGn, a major component of the total hCG imxnunoreactivity found in both urine and serum (25, 26) , is also poorly detected by this assay (11 In conclusion, we have established decision limits above which concentrations of hOG in urine can be considered abnormal. We have also shown that urine samples from individuals representative of the population at large, even when concentrated as much as sevenfold, contain less hOG than the described limit of abnormality.
In a nonconcentrated, ultrailltered urine sample presented by a male athlete, a finding of hOG at 10 lU/b, twice the value of our decision limit for abnormality, would constitute a positive result. Use of the freeze-dried urinary QC material described (for hOG at the decision limit) in conjunction with hOG immunoprocedures measuring intact hOG or biologically active hOG molecules should aid the comparability of hOG measurements between test centers. The QO is available, upon request, to all international laboratories testing for hOG as part of the initiative against doping in sports.
